ArticleNeurochemical research2025
VDAC1 Inhibition Mitigates Inflammatory Status and Oxidative Stress in Epileptic Mice Treated with the Ketogenic Diet.
Article in Neurochemical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A membrane-disruptive action of VBIT-4 challenges its role as a widely used VDAC1 oligomerization inhibitor.eLife · 2026Article
- Targeting VDAC1 to protect against mitochondria-linked cell death pathways: apoptosis, pyroptosis, ferroptosis, and associated diseases.Apoptosis : an international journal on programmed cell death · 2026Article
- Unveiling the impact of bisphenol a exposure on gene expression and immune response in diabetic nephropathy through integrative toxicogenomics and molecular dynamics approaches.Diabetology & metabolic syndrome · 2025Article
- A Membrane-Disruptive Action of VBIT-4 Challenges Its Role as a Widely Used VDAC Oligomerization Inhibitor.bioRxiv : the preprint server for biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Due to the pleiotropic effects of ketogenic diet (KD) on pathophysiology, including inflammation and oxidative stress, medical personnels have been intensively exploring the application of it in the management of epilepsy. Meanwhile, the voltage-dependent anion channel 1 (VDAC1) is believed to be involved in regulating inflammatory and oxidative stress processes. However, the correlation between KD and VDAC1 in epilepsy has not been elucidated. Pilocarpine-induced chronic epilepsy model was utilized to examine the effects of VDAC1 antagonist VBIT-4 treatment on seizure activity, behavioral changes, inflammation, and oxidative stress under control diet (CD) and KD conditions, respectively. Chronic VBIT-4 administration mitigates seizure activity and behavioral abnormalities of epileptic mice under KD rather than CD conditions. Our further findings demonstrated that VBIT-4 treatment attenuates inflammatory response and oxidative stress in the hippocampi and serum samples of epileptic mice under KD rather than CD. Taken together, our data suggest a critical role of VDAC1 in mediating the anti-seizure efficacy of the KD, shedding light on developing novel therapeutic interventions to seizure control.
Indexed as
Identifiers
40085179What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.